Yuki Kageyama to Urologic Neoplasms
This is a "connection" page, showing publications Yuki Kageyama has written about Urologic Neoplasms.
Connection Strength
0.830
-
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-?-induced Apoptosis in Urothelial Cancer. Anticancer Res. 2024 May; 44(5):1925-1930.
Score: 0.226
-
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021 Mar; 70(3):657-665.
Score: 0.175
-
Infrequent mutations of the WT1 gene in primary cancers of the adult urinary tract. Jpn J Clin Oncol. 1995 Oct; 25(5):173-8.
Score: 0.125
-
Bimodal pattern of the impact of body mass index on cancer-specific survival of upper urinary tract urothelial carcinoma patients. Anticancer Res. 2014 Oct; 34(10):5683-8.
Score: 0.116
-
The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007 Aug; 100(2):269-73.
Score: 0.070
-
Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006 Jun; 97(6):1322-6.
Score: 0.065
-
Increased expression of sialyl-Lewis A correlates with poor survival in upper urinary tract urothelial cancer patients. Anticancer Res. 2003 Jul-Aug; 23(4):3441-6.
Score: 0.053